Alpha-1 Proteinase Inhibitor (Aralast NP, Glassia, Prolastin-C, Zemaira)

Covers Aralast NP, Glassia, Prolastin‑C, and Zemaira only for chronic augmentation/maintenance therapy in clinically evident emphysema from severe congenital alpha‑1 antitrypsin deficiency and excludes off‑label uses. Approval requires documented AAT <11 µmol/L (80 mg/dL), FEV1 <80% predicted, nonsmoker/ex‑smoker status, absence of IgA deficiency with anti‑IgA antibodies, supporting clinical/spirometry/lab documentation, and is authorized for up to 12 months (with infectious‑agent transmission risks noted).

"For chronic augmentation and maintenance therapy in individuals with clinically evident emphysema due to severe congenital deficiency of alpha-1 proteinase inhibitor (alpha-1 antitrypsin deficiency)"

Sign up to see full coverage criteria, indications, and limitations.